In phase I (safety) trials, we have demonstrated the feasibility of autologous hematopoietic stem cell transplantation (HSCT) for patients with autoimmune diseases. Although this review comments on results of our phase I trials, the focus is on phase II (efficacy) trials using gene-marked autologous stem cells.
- Autoimmune disease
- Gene-marked autologous stem cells
- Hematopoietic stem cell transplantation
ASJC Scopus subject areas
- Immunology and Allergy